Dysfunction of endothelial precursor subtypes dictates the outcomes of diabetic r

内皮前体亚型的功能障碍决定了糖尿病患者的结局

基本信息

项目摘要

DESCRIPTION (provided by applicant): Endothelial progenitor cell (EPC) dysfunction may have a key role in the pathogenesis of DR. Two populations of EPCs that arise from cultured mononuclear cells (MNC) are the late outgrowth endothelial cells (OECs), which display a clonal phenotype and belong to a CD34+CD45- population; and early EPCs (eEPCs) which exhibit a monocyte phenotype (CD14+/CD45+) but demonstrate endothelial-like markers and behavior in vitro and in vivo. To address the role of these cells in diabetic retinopathy (DR) we hypothesized that in DR, eEPCs remain as the central modulator of the OECs; however, the OEC population is transiently lost in nonproliferative diabetic retinopathy (NPDR) but it reappears as a more aggressive and proliferative population which triggers the "angiogenic" switch and the onset of proliferative (PDR). The eEPC population, in contrast, never disappears entirely but rather shifts in its level of activity, being more inflammatory in PDR and less in NPDR. In both populations, dysregulation of nitric oxide synthase (NOS) is central to these phenotypic transitions, which are further influenced by the changing bone marrow (BM) microenvironment. We are testing this hypothesis by the following aims: Specific Aim 1: To test whether the proliferative potential of eEPCs and OECs depends on the stage of retinopathy and determine whether eEPCs and OECs isolated from diabetic individuals produce more reactive oxygen species, contain more endogenous NOS inhibitors, and secrete a distinct cytokine profile than cells from controls. Specific Aim 2: To test whether the combination of nondiabetic (healthy) eEPCs and OECs will have a greater reparative function then either population alone in models of retinal ischemia-reperfusion injury or in acellular capillaries in diabetic SCID mice. Specific Aim 3: To test whether eEPC and OEC dysfunction in diabetes is due to defects (increased adiposity, reduced hematopoiesis and progenitor dysfunction) in the BM microenvironment. These studies will allow us to determine whether eEPCs and OECs represent ideal progenitor populations for cellular therapy to improve the health of the vasculature in the diabetic eye.
描述(申请人提供):内皮祖细胞(EPC)功能障碍可能在DR的发病机制中具有关键作用。由培养的单核细胞(MNC)产生的两个EPC群体是晚期生长内皮细胞(OEC),其显示克隆表型并且属于CD 34 + CD 45-群体;以及早期EPCs(eEPCs),其表现出单核细胞表型(CD 14 +/CD 45+),但在体外和体内显示出内皮样标志物和行为。为了解决这些细胞在糖尿病视网膜病变(DR)中的作用,我们假设在DR中,eEPCs仍然是OEC的中心调节剂;然而,OEC群体在非增殖性糖尿病视网膜病变(NPDR)中短暂丢失,但它再次出现为更具侵略性和增殖性的群体,触发“血管生成”转换和增殖性(PDR)的发作。相比之下,eEPC群体从未完全消失,而是其活性水平发生变化,在PDR中更具炎症性,而在NPDR中较少。在这两个群体中,一氧化氮合酶(NOS)的失调是这些表型转变的核心,这进一步受到骨髓(BM)微环境变化的影响。具体目的1:检测eEPC和OEC的增殖潜力是否取决于视网膜病变的阶段,并确定从糖尿病个体分离的eEPC和OEC是否产生更多的活性氧,含有更多的内源性NOS抑制剂,并分泌与对照细胞不同的细胞因子谱。具体目标二:为了测试非糖尿病(健康)eEPC和OEC的组合是否将具有比在视网膜缺血-再灌注损伤模型中或在糖尿病SCID小鼠的脱细胞毛细血管中单独的群体更大的修复功能。具体目标3:测试糖尿病中的eEPC和OEC功能障碍是否是由于BM微环境中的缺陷(肥胖增加、造血减少和祖细胞功能障碍)所致。这些研究将使我们能够确定eEPCs和OECs是否代表细胞治疗的理想祖细胞群体,以改善糖尿病眼睛中血管系统的健康。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Maria Bartolomeo Grant其他文献

Maria Bartolomeo Grant的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Maria Bartolomeo Grant', 18)}}的其他基金

Correction of diabetic retinopathy by mitochondrial transfer
通过线粒体转移纠正糖尿病视网膜病变
  • 批准号:
    10658455
  • 财政年份:
    2023
  • 资助金额:
    $ 36.8万
  • 项目类别:
Dysfunction of endothelial precursor subtypes dictates the outcomes of diabetic r
内皮前体亚型的功能障碍决定了糖尿病患者的结局
  • 批准号:
    8473864
  • 财政年份:
    2013
  • 资助金额:
    $ 36.8万
  • 项目类别:
Vascular Reparative Mechanism by ACE2/Ang-(1-7)in Diabetes
ACE2/Ang-(1-7)在糖尿病中的血管修复机制
  • 批准号:
    8502551
  • 财政年份:
    2011
  • 资助金额:
    $ 36.8万
  • 项目类别:
Vascular Reparative Mechanism by ACE2/Ang-(1-7)in Diabetes
ACE2/Ang-(1-7)在糖尿病中的血管修复机制
  • 批准号:
    8325567
  • 财政年份:
    2011
  • 资助金额:
    $ 36.8万
  • 项目类别:
Vascular Reparative Mechanism by ACE2/Ang-(1-7)in Diabetes
ACE2/Ang-(1-7)在糖尿病中的血管修复机制
  • 批准号:
    8725220
  • 财政年份:
    2011
  • 资助金额:
    $ 36.8万
  • 项目类别:
Vascular Reparative Mechanism by ACE2/Ang-(1-7)in Diabetes
ACE2/Ang-(1-7)在糖尿病中的血管修复机制
  • 批准号:
    8189558
  • 财政年份:
    2011
  • 资助金额:
    $ 36.8万
  • 项目类别:
NO Dysregulation of the Peripheral Clock in Diabetic Complications
糖尿病并发症中没有外周时钟失调
  • 批准号:
    8721059
  • 财政年份:
    2010
  • 资助金额:
    $ 36.8万
  • 项目类别:
NO Dysregulation of the Peripheral Clock in Diabetic Complications
糖尿病并发症中没有外周时钟失调
  • 批准号:
    8152123
  • 财政年份:
    2010
  • 资助金额:
    $ 36.8万
  • 项目类别:
NO Dysregulation of the Peripheral Clock in Diabetic Complications
糖尿病并发症中没有外周时钟失调
  • 批准号:
    8304286
  • 财政年份:
    2010
  • 资助金额:
    $ 36.8万
  • 项目类别:
NO Dysregulation of the Peripheral Clock in Diabetic Complications
糖尿病并发症中没有外周时钟失调
  • 批准号:
    8026768
  • 财政年份:
    2010
  • 资助金额:
    $ 36.8万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 36.8万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.8万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 36.8万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.8万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 36.8万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.8万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 36.8万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 36.8万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 36.8万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.8万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了